Renal Cell Carcinoma News

Cabozantinib Effective Regardless of PD-L1 Expression in RCC

Cabozantinib Effective Regardless of PD-L1 Expression in RCC

PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.

Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks

Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks

A flat-dosing schedule of nivolumab (480 mg every 4 weeks) showed pharmacologic activity and safety similar to other schedules.

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

Long-term oncologic outcomes of patients with sporadic RCC who underwent robotic tumor enucleation suggest the procedure is safe.

Drug Targeting ENPP3 Is Active in Heavily Pretreated, Advanced Metastatic RCC

Drug Targeting ENPP3 Is Active in Heavily Pretreated, Advanced Metastatic RCC

An antibody-drug conjugate targeting ectonucleotide pyrophosphatase/phosphodiesterase 3 conjugated to monomethyl auristatin F had some antitumor activity in patients with advanced, metastatic renal cell carcinoma.

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.

A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer

A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer

Research focused on renal cell carcinoma appears to confirm the potential etiologic role of vitamin D binding protein in cancer.

Certain Renal Cancer Subtypes Linked to Obesity

Certain Renal Cancer Subtypes Linked to Obesity

Obesity is associated with an increased likelihood of clear cell and possibly chromophobe renal cell carcinoma.

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

Approval was based on results from the randomized phase 3 CheckMate-214 study.

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

The standard schedule is associated with AEs including grade 3 to 4 fatigue, HFS, and diarrhea.

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

Previous studies showed that combination therapy with nivolumab and ipilimumab has promising efficacy for various cancers, including RCC, compared with either agent alone.

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs